ERBB2 and breast carcinoma: In agreement with what was previously shown by Wilson et al. [62], in HER2+ breast cancers, Neuregulin-1b suppressed the response to anti-HER2 compounds through increased expression of the transcription factor forkhead box protein A1 (FOXA1) and HER3 [72].